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Neuropsychiatric symptoms of Alzheimer’s disease (NPS-AD) are highly prevalent and lead to poor medical and
functional outcomes. In spite of the burdensome nature of NPS-AD, we are continuing to refine the nosology and
only beginning to understand the underlying pathophysiology. Cluster analyses have frequently identified three to
five subsyndromes of NPS-AD: behavioral dysfunction (for example, agitation/aggressiveness), psychosis (for example,
delusions and hallucinations), and mood disturbance (for example, depression or apathy). Recent neurobiological
studies have used new neuroimaging techniques to elucidate behaviorally relevant circuits and networks associated
with these subsyndromes. Several fronto-subcortical circuits, cortico-cortical networks, and neurotransmitter systems
have been proposed as regions and mechanisms underlying NPS-AD. Common to most of these subsyndromes is the
broad overlap of regions associated with the salience network (anterior cingulate and insula), mood regulation (amygdala),
and motivated behavior (frontal cortex). Treatment strategies for dysregulated mood syndromes (depression and apathy)
have primarily targeted serotonergic mechanisms with antidepressants or dopaminergic mechanisms with
psychostimulants. Psychotic symptoms have largely been targeted with anti-psychotic medications despite
controversial risk/benefit tradeoffs. Management of behavioral dyscontrol, including agitation and aggression
in AD, has encompassed a wide range of psychoactive medications as well as non-pharmacological approaches.
Developing rational therapeutic approaches for NPS-AD will require a firmer understanding of the underlying etiology
in order to improve nosology as well as provide the empirical evidence necessary to overcome regulatory and funding
challenges to further study these debilitating symptoms.Introduction
Alzheimer’s disease (AD) is the most common neurode-
generative condition in aging. AD is a growing public
health problem that is projected to reach epidemic pro-
portions if disease-modifying therapies are not found.
The latest figures from the Alzheimer’s Association indi-
cate that an estimated 5.3 million Americans live with
AD. By 2050, an estimated 11 to 16 million people are
expected to be diagnosed in the US alone [1]. Data from
Alzheimer’s Disease International forecast that the
worldwide prevalence of AD will double every 20 years
to 65.7 million by 2030 and 115.4 million by 2050 with
higher proportions in the developed versus undeveloped
countries [2-4]. The economic costs of caring for persons
with AD are staggering. The Alzheimer’s Association
estimates that total health-care costs for persons with* Correspondence: mnowran1@jhmi.edu
Division of Geriatric Psychiatry and Neuropsychiatry, Department of
Psychiatry and Behavioral Sciences, Johns Hopkins University School of
Medicine, 5300 Alpha Commons Dr, 4th Floor, Baltimore, MD 21225, USA
© 2015 Nowrangi et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.AD are expected to top $172 billion, including $123
billion in costs to Medicaid and Medicare alone [5],
even without taking into account the ‘indirect costs’ of
providing care such as caregiver loss of productivity
and use of long-term care facilities and hospice.
The dementia syndrome stemming from the patho-
logical processes underlying AD results in cognitive,
functional, and behavioral symptoms [6]. Diagnosis of
dementia due to AD is based primarily on the clinical
presence of cognitive and functional impairment. The
most recent consensus statement from the National
Institute on Aging and the Alzheimer’s Association
workgroup has proposed revised criteria incorporating
biomarker evidence of probable AD and represents a step
forward in the clinical evaluation of AD [7-9]. Although
there has been progress in developing diagnostic mo-
dalities, there has been less progress in the manage-
ment of the pathognomic cognitive symptoms and
functional sequelae and even less for the behavioral
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dimensional behavioral phenotypes commonly found in
AD. NPS-AD are highly prevalent (80% to 90%), and most
individuals with AD will exhibit one or multiple symp-
toms over the course of the illness [10-12]. Symptoms can
range from mild (depression, anxiety, irritability, and ap-
athy) to severe (agitation, aggression, aberrant vocaliza-
tions, hallucinations, and disinhibition, among others).
These symptoms have been shown to persist or recur over
time and are associated with patient and caregiver distress,
increased rates of institutionalization, and increased
mortality [13-16]. Management of these symptoms has
relied on the use of both pharmacological and non-
pharmacological therapies based on treatments devel-
oped for idiopathic psychiatric disorders. A key reason
for the limited effectiveness and lack of progress for the
development of these treatments is an incomplete un-
derstanding of the biological mechanisms responsible
for these symptoms. As such, current treatment strategies
are considered symptomatically driven and treatment
development largely empiric rather than being based on
a mechanistic understanding. Thus, we are lacking an
essential piece in rational therapeutics.
In an effort to better understand the management of
NPS-AD, this article will review the current literature on
the phenomenology and diagnosis, neurobiology, and
treatment approaches for several key behavioral pheno-
types in AD. It is hoped that a summary of these find-
ings at this point will encourage further research by
demonstrating gaps in our knowledge of these condi-
tions while emphasizing the growing burden of these
symptoms on patients and caregivers as well as the need
for more effective therapies.
Phenomenology, detection, and classification of
neuropsychiatric symptoms of Alzheimer’s disease
Understanding the presentation of NPS-AD has generally
followed inductive reasoning. Colloquially known as the
‘duck test’ approach, similarities between two ideas or ob-
jects or, in this case, conditions are made and conflated or
used interchangeably. That is, ‘if it walks like a duck,
swims like a duck, quacks like a duck, it must be a duck’.
These are essentially analogs of symptoms from idiopathic
psychiatric disorders (that is, disorders of emotion, thought,
or behavior for which there is no definitive pathophysi-
ology). For example, if an individual with AD were to ex-
hibit lack of reactivity or report low mood, poor appetite,
or disordered sleep, a diagnosis of depression in AD may
be given. Similarly, if an individual exhibits hallucinations
or delusions or psychomotor activation, a diagnosis of
psychosis may be offered to explain the phenomenon. Gen-
erally then, the descriptions of these phenomena, based on
first-person experience (direct and primary observation),
generate diagnoses, which direct treatment decisions.Detection of NPS-AD has relied primarily on caregiver-
reported scales. The most commonly used scale is the
Neuropsychiatric Inventory (NPI) [17,18], which has been
considered the standard assessment for neuropsychiatric
symptoms for the past two decades by assessing symp-
toms in 12 domains (Table 1). Recently, a revised version
of the NPI, the Neuropsychiatric Inventory Clinician re-
ported (NPI-C) [19], has been developed to address sev-
eral shortcomings of the NPI and other rating scales and
is a well-validated and commonly used scale. A major im-
provement of the NPI-C was the addition of a clinician
rating methodology, which mitigates the reliance on
caregiver-provided information and in so doing sys-
tematizes the way in which clinical observation and
caregiver report are integrated. There are alternate ver-
sions of the NPI, including (a) NPI-NH [20], designed
for use in the nursing home setting, and (b) the NPI-Q
[21], a brief caregiver report questionnaire that can be
completed in 5 minutes or less and has good test-retest
reliability and convergent validity correlating with the
full NPI at 0.91 [21,22].
As a result of these empirical approaches, the search
for etiology has generated and continues to generate bio-
logical and neuropathological as well as psychosocial hy-
potheses. This has led to considerable heterogeneity in
classifying these symptoms. Subcategorizing by associa-
tive clustering has been one approach to understanding
potentially differential prevalences, trajectories, and bio-
logical mechanisms. One of the earliest attempts of this
was with the Cache County study, in which 198 individ-
uals with AD were identified in a cohort of 5,092 older
residents [23]. When the NPI and neuropsychiatric
evaluation were used, three latent classes of symptoms
were identified: primarily affective symptoms (28%), primar-
ily psychotic symptoms (13%), and mono-symptomatic
disturbance (19%); the remainder had no symptoms
(40%). More recent cross-sectional and longitudinal
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factors by using principal component factor analysis
[24]. A study by Vilalta-Franch and colleagues [25] fur-
ther described a ‘hypomanic’ group in which euphoria
and disinhibition clustered together.
The elucidation of these factors has been the result of
numerous studies frequently employing latent class ana-
lysis, in which the latent factor is expressed as the math-
ematical property of all the observed variables [26-31].
Because of this and other statistical challenges inherent
in exploratory factor analysis employed by earlier stud-
ies, Cheng and colleagues [32] recently used an alterna-
tive method in which the statistical approach started by
using hypothetical behavioral syndromes that made ‘clin-
ical sense’ to guide confirmatory factor analysis. Their
analysis supported a four-factor model: (1) behavioral
problems (agitation/aggressiveness, disinhibition, irritabil-
ity, and aberrant motor behavior), (2) psychosis (delusions
and hallucinations), (3) mood disturbance (depression,
sleep, appetite, and apathy), and (4) euphoria. These stud-
ies appear to provide an evidence-based foundation for
the classification of NPS-AD and further represent an
evolution in the nosology of these symptoms; however, the
lack of consistency and presence of contradictions within
the available data continue to be limitations. A systematic
review by Canevelli and colleagues [24], who evaluated the
evidence coming from factor analyses involving the use of
the NPI, showed a relatively low concordance among
available evidence for clusters represented in the NPI. In
fact, no study reported the same cluster composition of
another one. However, this review did find consistent as-
sociation of specific symptoms across studies that may po-
tentially define behavioral subsyndromes of AD: delusions
and hallucinations, depression and anxiety, agitation and
irritability, and euphoria and disinhibition were found to
be frequently associated symptoms characterizing possible
phenotypes as previously mentioned. Nonetheless, there
remain considerable gaps in our knowledge primarily
driven by our nascent understanding of the underlying
biology.
Neurobiology of neuropsychiatric symptoms of
Alzheimer’s disease
Although there have been significant advances in under-
standing the functional neuroanatomy, neurochemistry,
and neurophysiology of cognitive phenotypes (memory,
language, visuospatial ability, and executive functions),
there has been less progress in understanding more
complex behavioral phenotypes associated with AD.
State-of-the-art structural and functional neuroimag-
ing approaches have been widely used to study the core
pathological processes of AD and are just starting to be
applied to NPS-AD. For these reasons, current re-
search in the neurobiology of NPS-AD is driven byaccepting the assumptions first that neuropsychiatric
symptoms are accurately measured in AD and second
that NPS-AD is related to changes in brain structure
and function that point toward underlying mechanisms
of behavior that may or may not be shared with other
neuropsychiatric or idiopathic psychiatric disease. The
implication of brain circuits and networks as revealed
through current research reflected a paradigm shift in
understanding the relationship between brain and behavior
[33]. Born out of Norman Geschwind’s pioneering work in
disconnection syndromes, a ‘disconnectionist’ framework
provided the field with the understanding that higher
function deficits resulted from lesions of white matter
in association cortices that act as relay stations between
primary motor, sensory, and limbic areas [34]. With the
advent of neuroimaging and other neurophysiological
techniques, it has now become possible to study con-
nections in vivo and make correlations between discon-
necting lesions or processes and clinical symptoms.
As part of a recent initiative by the Alzheimer’s Association,
the Neuropsychiatric Syndromes of AD Professional Interest
Group of the International Society to Advance Alzheimer’s
Research and Treatment, Geda and colleagues [35] re-
cently put forth a tripartite hypothetical model based on
empirical research to guide the further study of NPS-AD.
The first hypothesis is that at least three frontal-subcortical
circuits (dorsolateral prefrontal circuit, orbitofrontal pre-
frontal circuit, and circuit involved in motivated behavior)
mediate human behavior. The second hypothetical model
posits that cortico-cortical networks, of which five have
been frequently cited, mediate emotional as well as cogni-
tive processing. Finally, the third model suggests that the
monoaminergic system involving such neurotransmitters
as serotonin, norepinephrine, and dopamine along white
matter projections from rostral to caudal brain regions
mediate complex behavior. Certainly, modulation of gluta-
matergic [36], neurotrophic (for example, brain-derived
neurotrophic factor) [37], and other neurochemical and
neuroendocrine systems has also received attention as re-
lated mechanisms of action [38]. A brief review of specific
contributions of neurotransmitter and neuroimaging stud-
ies to our understanding of mechanisms of NPS-AD are
summarized in Table 2 and are expanded upon below.
Depression
There is evidence for alterations in monoaminergic neuro-
transmitter functioning and brain metabolism underlying
depression in AD. For example, there is evidence for se-
lective loss of 5HT1A receptors in the hippocampus [39]
as well as loss of noradrenergic neurons in locus coeruleus
and serotoninergic neurons in the raphe nucleus [40-42].
These findings represent additional functional loss of sero-
tonergic neurotransmission over and above the substantial
losses observed in AD in general [43,44] which selectively






Neurotransmitter mechanisms Neuroimaging correlates Treatments
Depression Monoaminergic, noradrenergic,
gamma amino butyric acid (GABA)
neurotransmission dysfunction
Reduced entorhinal cortex thickness;
accelerated atrophy in anterior cingulum;
decreased cerebral glucose in frontal and
parietal cortex
Serotonin (serotonin selective reuptake
inhibitor, or SSRI), norepinephrine
(serotonin-norepinephrine reuptake
inhibitor, or SNRI), non-pharmacological
treatments
Apathy Lower dopamine transporter binding;
lower cholinergic receptor binding
Decreased metabolic activity in anterior
cingulate and orbitofrontal cortex;








increased D2/D3 receptor availability;
monoaminergic (5-HT2A) transmission
defects
Cortical atrophy of cingulum and frontal
gyrus; insula, amygdala, and hippocampal
atrophy; lower metabolic activity in





Psychosis D2/D3 receptor availability,
monoaminergic, cholinergic
Lower regional cerebral blood flow in angular
gyrus and occipital lobe; increased atrophy in
neocortical, frontal, parietal and cingulum
Atypical anti-psychotics, non-pharmacological
treatments
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forebrain cholinergic neurons are relatively spared in de-
pressed patients with AD [46,47]. Additionally, there is
evidence for decreased gamma amino butyric acid
(GABA) levels and greater number of GABA (A) receptors
in depressed patients with AD [48]. Studies of genetic
polymorphisms in serotonin and dopaminergic trans-
porters and receptors have not distinguished depressed
versus non-depressed patients with AD. Zahodne and col-
leagues [49] reported that depression in mild cognitive im-
pairment (MCI) was associated with reduced cortical
thickness in the entorhinal cortex at baseline and acceler-
ated atrophy in the anterior cingulate cortex. They inter-
preted this to mean that depression was associated with
the overall rate of neurodegeneration in AD or with re-
duced cognitive reserve. Several studies have demon-
strated lower cerebral glucose metabolism in depressed
versus non-depressed patients with AD in the frontal
(dorsolateral prefrontal cortex, superior frontal gyrus, and
anterior cingulate gyrus) or parietal cortex (post-central
gyrus and superior and inferior lobule) [50,51]. One study
observed that lower 5-HTT transporter density was corre-
lated with greater depression symptom severity [52].
These findings are in contrast to late-life major depres-
sion, including the observations of greater white matter
hyperintensities, increased cortical glucose metabolism,
and 5-HTT and 5-HT1A receptor loss, reviewed in Khan-
dai and Aizenstein [53] (2013) and Hirao and Smith [54]
(2014). Thus, the evidence indicates that decreased mono-
aminergic neurotransmitter function and decreased
fronto-parietal metabolism are involved in mechanisms of
depression in AD and that the metabolic changes are op-
posite to those observed in late-life major depression.Apathy
Lower dopamine transporter binding has been associ-
ated with decreased initiative [55], whereas lower cholin-
ergic receptor binding in the left frontal cortex has been
reported to be associated with motor and mood changes
of apathy [56]. These findings mirror successful treat-
ment of apathy in AD with the dopaminergic agent me-
thylphenidate (see below). Apathy has been associated
with decreased metabolic activity in anterior cingulate
and orbitofrontal cortex. There is growing evidence that
apathy in AD is associated with structural atrophy and
functional deficits in several medial and inferior frontal
regions thought to mediate motivation and reward
mechanisms [35]. Starkstein and colleagues [57] re-
ported that apathy was associated with greater volume
of white matter hyperintensities in frontal cortex, sug-
gesting a greater burden of small-vessel ischemic disease.
Marshall and colleagues [58] reported that apathy in AD
was associated with decreased metabolic activity in an-
terior cingulated and orbitofrontal cortex.
Agitation and aggression
There is evidence that agitation/aggression in AD is re-
lated to dysfunction of specific brain regions. There is
growing evidence that structural and functional deficits
may be related to deficits in cholinergic neurotransmis-
sion (over and above those seen in AD itself ) and with
increased D2/D3 receptor availability in the striatum. An
important study by Assal and colleagues [59] showed a
positive association between 5-HT2A receptor gene
polymorphism and agitation and aggression in AD,
suggesting a role for serotonin transmission defects.
Serra and colleagues [60] reported that disinhibition
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eral anterior cingulate and right middle frontal gyri. Bruen
and colleagues [61] reported a similar association of agita-
tion with grey matter atrophy in bilateral anterior cingu-
late and additionally in left insula. In a larger cohort of
participants in the Alzheimer’s Disease Neuroimaging Ini-
tiative, Trzepacz and colleagues [62] reported an associ-
ation of agitation severity with greater atrophy of frontal,
insular, amygdala, cingulate, and hippocampal regions.
Reeves and colleagues [63] reported that striatal dopamine
receptor D2/D3 binding - as measured by 11C-raclopride
positron emission tomography (PET) - was associated
with severity of delusions and disinhibition in AD. Sultzer
and colleagues [64,65] reported that agitation in AD cor-
related with lower metabolic activity (as measured by
fluorodeoxyglucose-PET) in right lateral temporal, right
lateral frontal, and bilateral cingulate cortex. Mielke and
colleagues [66] reported that lower structural integrity of
the fornix (as measured with diffusion tensor imaging)
was associated with agitation in AD. Balthazar and col-
leagues [67] reported that the NPI ‘hyperactivity factor’
(including agitation) was associated with greater resting-
state functional connectivity in the anterior salience net-
work, particularly in right anterior cingulate and insula.
When the biological evidence is fully considered, it ap-
pears that agitation/aggression in AD is associated
with cortical dysfunction in anterior cingulate, insula,
lateral frontal, and lateral temporal regions, many of
which are associated with the anterior salience network
thought to direct brain resources toward specific cog-
nitive activities [68].
Psychosis
A number of neurotransmitter systems have been impli-
cated in psychosis of AD. Increased availability of striatal
dopamine (D2/D3) as well as increased dopamine D3 re-
ceptor density in the nucleus acumbens has been found
in AD patients with psychosis, compared with those
without psychosis [69]. Additionally, a lower density of
5-HT receptors has been found in the ventral temporal
cortex and prosubiculum as well as increased ratio of
acetylcholinesterase/5-HT [70,71]. It has been suggested
that the lower 5-HT levels may be associated with lower
cell counts in the dorsal raphe nucleus in AD patients
with psychosis [72]. With regard to neuroanatomy, a
study by Banno and colleagues [73] showed that, when
studied with single-photon emission computed tomog-
raphy imaging, psychosis symptoms in AD were most
associated with lower regional cerebral blood flow values
in the right angular gyrus (Brodmann area 39) and the
right occipital lobe (Brodmann area 19). Rafii and col-
leagues [74] showed that regional atrophy rates in neo-
cortical, lateral frontal, lateral parietal, and anterior
cingulate gyrus were significantly associated with theonset of psychosis, including delusions, agitation, wander-
ing, and hallucinations and/or the need for anti-psychotic
medications. Findings from this study in particular are
consistent with other studies that similarly identify a
well-characterized corticosubcortical circuit involving
the frontal gyri and the cingulate gyrus purportedly in-
volved in mediating complex intentional and motivated
behaviors as well as high-order cognitive functions such
as planning and problem solving [75-77]. It is suggested,
then, that a disconnection of this and other neocortical
networks is related to the presence of psychosis in AD.
What is most striking about the data from agitation,
depression, apathy, and psychosis in AD is the broad
overlap of regions associated with each NPS syndrome,
particularly regions known to be associated with the sali-
ence network (anterior cingulate and insula), mood regu-
lation (amygdala), and motivated behavior (frontal cortex).
This suggests at least partial overlap of brain mechanisms
subsuming these NPS.
Management of common neuropsychiatric
syndromes in Alzheimer’s disease
The most common NPS-AD are depression, apathy, delu-
sions and hallucinations, and agitation and aggression,
with point and 5-year prevalence ranging between 20%
and 50% according to the Cache County cohort [14].
These symptoms can be and have been clustered into
affective, psychotic, and behavioral dyscontrol syndromes
as discussed earlier. Given this high prevalence as well as
the deleterious social and financial effects, we now turn
our focus to management principles of these syndromes.
Management of depression and apathy in Alzheimer’s
disease
Depression and apathy are the most common affective
symptoms in AD. Depressive symptoms have been hy-
pothesized to be related in part to disturbances in the
monoaminergic system involving neurotransmitters such
as serotonin, norepinephrine, and dopamine in non-AD
conditions such as major depression as referenced earlier.
As such, the majority of pharmacological interventions
are targeted at alleviating depressive symptoms primarily
to improve quality of life and improve functioning in AD
and secondarily to mitigate factors exacerbating cognitive
impairment and hindering the efficacy of pro-cognitive
drugs and other non-pharmacological interventions. Anti-
depressant medications have been most frequently studied
in comorbid depression in AD. A recent meta-analysis by
Sepehry and colleagues [78], however, paints a rather un-
enthusiastic picture for the use of anti-depressant medica-
tions. After applying inclusion and exclusion criteria, the
authors selected six studies/trials from which an aggregate
of 297 participants enrolled in treatment arms and 318 en-
rolled in placebo arms. Via random-effects modeling, the
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sion nested analyses using the Cornell Scale for Depres-
sion in Dementia and the Hamilton Depression Rating
Scale. In spite of this, the authors caution that clinical
choice of specific serotonin selective reuptake inhibitors
other than sertraline, which the majority of the selected
studies tested, may differentially affect outcomes, includ-
ing potentially positive effects because of differences in
pharmacological action on serotonin receptor subunits.
Studies testing serotonin-norepinephrine reuptake inhibi-
tor medications did not meet this meta-analysis inclusion
criteria, but studies of venlafaxine [79], for example, have
resulted in mixed findings.
Apathy is differentiated from depression in that individ-
uals suffer from diminished motivation as demonstrated
by decreased goal-directed behavior, decreased goal-
directed cognitive activity, and constricted or blunted
affective range. Neurobiologically, apathy has been associ-
ated with dysfunction of the prefrontal and anterior cin-
gulate regions, including both cortical and subcortical
regions, with causes ranging from volume loss to in-
creased burden of white matter hyperintensities to de-
creases in regional cerebral blood flow to increases in
prefrontal Aβ deposition [80]. Moreover, overlaps found
between apathy and executive dysfunction have caused
some speculation that the thalamic-prefrontal-subcortical
circuitry is shared between the two. Unfortunately, few
controlled trials target treatment of apathy in AD. One re-
cent randomized placebo-controlled trial of methylphen-
idate for apathy in AD (ADMET) reported improvement
in two out of three efficacy outcomes with a trend toward
improved global cognition with minimal adverse events
[81-83]. Few other uncontrolled trials, however, have also
shown treatment effects with methylphenidate [84,85] and
one with donepezil [86]. Other medications, including
amantadine [87], d-amphetamine [88], and modafanil
[89], have shown mixed results.
Management of psychotic symptoms in Alzheimer’s
disease
Individuals with AD and psychotic symptoms tend to
suffer greater functional decline, increased rates of
institutionalization, and increased mortality and in-
creased caregiver burden even after controlling for age,
gender, cognitive and functional disability, general
health status, and use of anti-psychotic treatment [90].
The symptoms are characterized by auditory or visual
hallucinations (or both) and delusions such as paranoia
and persecution.
Treatment of psychotic symptoms in AD is based on
severity and frequency of symptoms as well as the disabil-
ity resulting from them and weighing risks and benefits
of using anti-psychotic medications when other non-
pharmacological measures and potentially medical causeshave been ruled out. Use of anti-psychotic medications
such as atypical and typical neuroleptic medications
should be reserved as a last resort because of the poten-
tially dangerous side effects and limited to modest benefit
these provide. Large-scale meta-analyses consistently
demonstrate a 1.5- to 1.7-fold increase in mortality when
atypical anti-psychotic medications are used [91,92]. As a
result, the US Food and Drug Administration has included
a ‘black-box’ warning for atypical anti-psychotics, caution-
ing about increased mortality and risk of cerebrovascular
accidents. Other adverse effects include cardiovascular
and metabolic derangements, extrapyramidal motor symp-
toms, cognitive worsening, infections, and falls. The large
Clinical Antipsychotic Trials of Intervention Effectiveness
Alzheimer’s Disease trial showed non-significant treatment
effects of three anti-psychotics (olanzapine, quetiapine,
and risperidone) when compared with placebo. Moreover,
time to discontinuation due to intolerable side effects was
higher for those taking the anti-psychotics versus placebo
[93,94]. Results from a recent study by Lopez and col-
leagues [95] challenge these findings and warnings by
showing that the subset of their cohort exposed to neuro-
leptic drugs did not show a relationship to increased mor-
tality or increased institutionalization when controlling for
the psychiatric symptoms for which the drugs were pre-
scribed. These results suggest that, when adjusting for
relevant covariates, the presence of psychiatric symptoms,
including psychosis and agitation, was linked to poor
outcomes rather than the medications themselves.
Taken together, these results as well as the limited effi-
cacy of these medications point to significant gaps in
our knowledge of the specific neurobiology of these
symptoms in AD compared with other psychotic disor-
ders such as schizophrenia.
Management of agitation and aggression in Alzheimer’s
disease
Agitation and aggression have frequently been termed
‘dysexecutive’ symptoms because of their relationship to
‘executive’ or higher-order loss of behavioral control
[96-98]. Relevant domains on the NPI-C include agita-
tion, aggression, irritability/lability, aberrant motor
behavior, and aberrant vocalizations. Disruptions in
prefrontal-subcortical-thalamic circuits as well as other
cortico-cortical circuits have been proposed as neuro-
anatomical substrates related to these symptoms as pre-
viously discussed. Neurotransmitter systems along these
circuits have included dopaminergic, noradrenergic, se-
rotonergic, acetylcholinergic, and other systems as po-
tentially exerting some modulatory effect. In spite of the
associated neurobiology, the literature continues to lack
general agreement on either symptom classification or
identification and treatment. For example, serotonergic
treatment with citalopram in the Citalopram for Agitation
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on outcome measures of agitation that was clinically
meaningful on a global functioning scale compared with
those who received placebo, whereas studies of dopamine
augmentation [101] with medication such as amantadine
have shown some modest treatment effects [102]. Use of
atypical anti-psychotic medications (see above) as well as
anti-epileptic mood stabilizers such as valproic acid
[103-105] has become a mainstay in the treatment of
these behaviors but similarly carries considerable risk.
Non-pharmacological treatments
Non-pharmacological treatments (NPTs) encompass
such interventions as cognitive stimulation, cognitive train-
ing, behavioral interventions, exercise, music, and multi-
sensory stimulation for those with dementia. NPTs can also
be guided toward caregivers and include education, sup-
port, case management, and respite care. As such, a wide
range of different types of therapies have been studied.
Some small studies have shown modest benefit with strat-
egies such as aromatherapy, bright light therapy, and
music therapy. Behavior therapy using antecedent-
behavior-consequence (ABC) diary assessment has pro-
vided good sustained improvements in behavior [106,107].
One meta-analysis found that behavioral management
techniques focused on individual patients’ behavior and
individually oriented psychoeducation provided longer-
lasting (several months) positive effects on behavior when
compared with placebo [106]. Music therapy and Snoeze-
len were two other types of therapies that provided posi-
tive yet short-lived effects. Finally, staff education has
been shown to lead to reductions in behavioral outbursts
and fewer episodes of restraint use. Despite the promising
results from these studies, there is little controlled evi-
dence that they in fact work, and they are often diffi-
cult to implement in real-world settings. In a meta-
analysis by Olazarán and colleagues [108], the majority
of the studies (randomized controlled trials) reviewed
showed positive effects for improvements in mood, be-
havior, and quality of life of persons with dementia
while delaying institutionalization. The quality and depth
of these studies should continue to be improved upon
to further provide empirical support for the use of NPT
in AD. Funding for this type of work, unfortunately, has
become a limitation.
Conclusion: treatment development and where to
go from here
Rationally developing disease and symptom-specific ther-
apies such as those for NPS-AD requires a firmer under-
standing of etiology. In this case, advances are being made
to further elucidate the neural underpinnings of NPS-AD
and will include contributions from neuroimaging, etio-
pathological studies, and other areas of basic and clinicalneuroscience to test the hypotheses put forth by Geda
and colleagues [35]. With increasing focus on pre-
morbid states such as MCI, studying the link between
NPS in MCI, mild behavioral impairment [109], and de-
mentia onset should also provide significant insight into
etiology. Understanding brain-behavior relationships in
terms of neural circuits and behaviorally (as well as cog-
nitively) relevant networks has been an important devel-
opment which has revolutionized the way we think about
designing and developing as well as monitoring the effects
of interventions. Further research into developing the
technologies that will be used to elucidate these substrates
ought to become a major area of focus over the next dec-
ade. In the interim, continued development of patient/
caregiver and clinician assessment tools such as the NPI
should continue to be standardized for different popula-
tions of individuals.
Important challenges to continued research in this area
include regulatory and funding limitations. Definitions
of these symptoms continue to garner inconsistency and
disagreement and have been a fundamental gap in un-
derstanding (and naming) disease syndromes as well as
obtaining regulatory approval and governmental fund-
ing. Certainly, progress is being made as definitions of
depression, apathy, and psychosis have gained increas-
ing levels of consensus. Definitions of agitation and
other neuropsychiatric symptoms require further work
in describing the phenomena and classifying them. In
order for the US Food and Drug Administration to
‘carve out’ additional NPS targets for drug development,
well-defined symptom clusters must be provided and be
supported by widespread acceptance in the clinical/
academic communities. Another challenge would be to
posit and defend the hypothesis that NPS-AD such as
depression is distinct in terms of phenomenology,
course, and response when compared with idiopathic
depression, for example. Bolstering efforts toward im-
proving clinical epidemiological studies that validate
proposed syndromes, identify risk and protective factors,
and provide high-quality naturalistic study designs will be
significant steps forward and provide further empirical
evidence needed to support applications for funding. With
growing pathophysiological knowledge, studies directed at
testing efficacy of novel therapies and especially ones that
integrate and sequence non-pharmacological and pharma-
cological approaches will provide a comprehensive ap-
proach that sets up discontinuation, safety, and long-term
outcome studies.Abbreviations
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